The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
Market Dynamics
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.
Key features of the study:
This report provides in-depth analysis of pulmonary drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market
Detailed Segmentation:
Global Pulmonary Drugs Market, By Drug Class:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
Global Pulmonary Drugs Market, By Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
Global Pulmonary Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Global Pulmonary Drugs Market, By Geography:
North America
By Drug Class:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
By Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
U.S.
Canada
Latin America
By Drug Class:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
By Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
By Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
By Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
By Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
By Application:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
E-Commerce
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Sanofi SA*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet, By Drug Class
? Market Snippet, By Application
? Market Snippet, By Distribution Channel
? Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Restraints
? Market Opportunities
? Market Trends
o Regulatory Scenario
o Pipeline Analysis
o Promotional Activities and Campaigns
o Supply Chain Analysis
o PEST Analysis
o Epidemiology
4. Global Pulmonary Drugs Market, By Drug Class, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Inhaled Corticosteroids
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Long Acting Beta-2 Agonists
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Antihistamines
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Vasodilators
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Short Acting Beta-2 Agonists
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Others
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
5. Global Pulmonary Drugs Market, By Application, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Asthma & COPD
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Allergic Rhinitis
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Pulmonary Arterial Hypertension
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Cystic Fibrosis
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Others
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
6. Global Pulmonary Drugs Market, By Distribution Channel, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Hospital Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o Retail Pharmacies
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
o E-Commerce
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
7. Global Pulmonary Drugs Market, By Region, 2017 - 2025, (US$ Million)
o Introduction
? Market Share Analysis, By Region, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, For Regions, 2017 - 2025
o North America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? U.S.
? Canada
o Latin America
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Brazil
? Mexico
? Rest of Latin America
o Europe
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? Germany
? U.K.
? France
? Italy
? Spain
? Russia
? Rest of Europe
o Asia Pacific
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? China
? India
? Japan
? Australia
? South Korea
? ASEAN
? Rest of APAC
o Middle East
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? GCC
? Israel
? Rest of Middle East
o Africa
? Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Application, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
? Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
? South Africa
? Central Africa
? North Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
? Sanofi SA*
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Meda Pharmaceuticals
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Circassia Pharmaceuticals Plc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? AstraZeneca Plc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? GlaxoSmithKline Plc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Mallinckrodt Pharmaceuticals Plc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Cheisi Farmaceutici S.p.A
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Zambon Company S.p.A
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Alaxia SAS
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Merck Sharp & Dohme Limited
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 50 market data tables and 38 figures on "Pulmonary Drugs Market - Global forecast to 2025".
Request Discount 
Inquire Before Buy
